Open Label Prostate Cancer Study

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

October 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

AZD3514

Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.

Trial Locations (5)

Unknown

Research Site, Portland

Research Site, Amsterdam

Research Site, Glasgow

Research Site, Manchester

Research Site, Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY